Should You Forget Eli Lilly and Buy This Magnificent Biotech Stock Instead?
Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has helped its earnings and its stock soar in recent times. It consists of the company's weight loss drugs: Mounjaro,
20hon MSN
After flying high during the first half of the year, pharmaceutical giant Eli Lilly (NYSE: LLY) has lost some momentum; the ...
The Health Resources and Services Administration has “invoked the nuclear option of removal from not only the 340B program ...
Eli Lilly and Company (NYSE: LLY) announced today that it has elected Jon Moeller as a new member of its board of directors ...
The Motley Fool on MSN4d
Is It Time to Sell Eli Lilly and Pfizer Stocks?Eli Lilly now ranks as the largest drugmaker in the world based ... Much of Lilly's recent dismal stock performance ...
GlobalData on MSN5d
Eli Lilly reports outcomes from Phase III trial of tirzepatide for HFpEFThe trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.
The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...
Earlier on Wednesday, Laekna, “a global biotech company focused on novel drug development for metabolic and cancer diseases,” accoding to its ...
The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback